How VCs at the AI-bio interface set up their portfolios for success

While life science VCs have long provided operational support to portfolio companies, the specific bottlenecks and opportunties at the AI interface are motivating some firms to take a more proactive role in supplying inputs such as data, analytics and tools, either directly or through other investments.

Building centralized capabilities can be a capital-intensive investment in and of itself, though in doing so firms can gain engines for future company or asset creation, and in some cases, portfolio companies may become paying clients of these services...